Outcomes researcher moves south to national nonprofit

Share this article:
Dave Davis, MD, the University of Toronto academic widely respected for his research on outcomes-oriented education, will join the Washington, DC-based Association of American Medical Colleges.

Davis will assume a new position for this nonprofit association—VP, continuing health
education and physician performance improvement in the division of med ed. AAMC oversees several initiatives aimed at improving med ed.

Davis, who currently leads the University of Toronto CME program, said he will work to up awareness of CME, its effectiveness and linkages to the health system. “To have an opportunity at the end of my career to spend time with colleagues who I value in CME across the nation is just a wonderful opportunity,” Davis told MM&M.

The announcement follows part of a sabbatical year Davis spent at AAMC.

ACCME’s updated compliance criteria also prompted the move. “It made me think some of these goals might be attained,” Davis said.

Davis’ current duties have included overseeing a knowledge translation program endowed by Li Ka Shing at Toronto’s St. Michael’s Hospital. He earlier created a CE division at Canada’s McMaster University. Davis said that, in some medical schools, QI in patient care and CME are not meshed well. “Clearly we need to bring those two dimensions together.”

He will begin his new post in late summer or fall as soon as he winds down his medical practice.
Davis will report to Carol Aschenbrener, MD, AAMC EVP.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.